



Global
Resource for
Advancing
Cancer
Education

Program Achievements and Reach

2022 Program Year



Reach in 2022: 35k+ patients with lung cancer and caregivers

Program Overview:

- Long-running patient education video program featuring top oncologists presenting the most current and emerging treatment options
- Short, 3-5 minute easy-to-understand videos as updates to the searchable online GRACE Lung Cancer Video Library
- Videos are transcribed so patients may print them and take them to their health care provider appointment


2022 Program Details/Achievements:

9 videos produced in 2022:

1. Combination Chemotherapy and Immunotherapy for Patients with High PD-L1 NSCLC
2. Driver Mutations and Their Role in NSCLC Treatment
3. Driver Mutation Testing: Managing Expectations
4. The Cost of Targeted Therapy
5. Small Cell Lung Cancer (SCLC): Histology and Staging
6. Treating Limited and Advanced Stage SCLC
7. Chemoimmunotherapy in SCLC
8. Recent Advances in SCLC Treatment
9. The Future of SCLC: Next Steps, Treatments, and Progress

Link to videos on GRACE website:

<https://cancergrace.org/video-collection/lung-cancer-video-library-english>



Reach in 2022: 25,000+ Spanish speaking patients with lung cancer and caregivers

- Spanish language patient education video program featuring top oncologists
- Short, 3-5 minute easy-to-understand Spanish-language videos as updates to the searchable online GRACE Lung Cancer Video Library
- Videos are transcribed so patients may print them and take them to their health care provider appointment.

2022 Program Details/Achievements:

3 videos produced at the time of this report:

1. *Liquid Biopsies: a Diagnostic Tool for Lung Cancer - Biopsias líquidas: Una Herramienta de Diagnóstico Para el Cáncer de Pulmón*
2. *The Importance of Lung Cancer Screening - La Importancia de la Detección del Cáncer de Pulmón*
3. *Neoadjuvant Immunotherapy + Chemo for Patients with NSCLC - Inmunoterapia Neoadyuvante + Quimioterapia Para Pacientes con NSCLC*

Additional topics that were subject of video content for the 2022 program year that are still in final production/editing at the time of this report:

1. New Agents RET, MET, KRAS - Nuevos Agentes Para las Mutaciones RET, MET, y KRAS
2. EBUS - ESTADIAJE DEL CÁNCER DE PULMÓN CON EBUS
3. Targeted Therapies for Resected Cancer – Terapias Dirigidas para Cáncer Resectado
4. First Line Therapies - Terapias de Primera Línea para Cáncer Avanzado del Pulmón
5. Targeted therapy for NSCLC (ALK and ROS-1) - TERAPIA DIRIGIDA PARA CANCER DE PULMON (ALK Y ROS-1)
6. Targeted therapy for NSCLC (EGFR) - TERAPIA DIRIGIDA PARA CANCER DE PULMON (EGFR)
7. Small cell lung cancer immunotherapy and targeted therapy - IMMUNOTERAPIA Y TERAPIA DIRIGIDA PARA CANCER DE PULMON DE CELULAR PEQUENAS
8. Terapia local para enfermedad oligometasática
9. Utilidad de Terapia de Protones en cancer
10. Inmunoterapia en cancer de pulmon de celulas pequenas
11. Manejo de pacientes con inhibidores EGFR y ALK
12. Indicaciones para inmunoterapia antes de la cirugía
13. Inmunoterapia para Cancer de pulmon localmente avanzado que viene despues de PACIFIC?

Link to videos on GRACE website:

<https://cancergrace.org/video-collection/lung-cancer-video-library-spanish>





Reach in 2022: 100,000+ patients with lung cancer and caregivers who speak East Asian languages

- East Asian language patient education video program featuring top oncologists
- Short, 3-5 minute easy-to-understand Mandarin-language videos with illustrative slides as updates to the searchable online GRACE Lung Cancer Video Library
- Videos are transcribed so patients may print them and take them to their health care provider appointment

2022 Program Details/Achievements:


10 videos produced in 2022:

1. *Lung Cancer Statistics* (肺癌统计)
2. *Distribution and Causes of Lung Cancer* (肺癌的分布和成因)
3. *Lung Cancer Screening Recommendations* (肺癌筛查建议)
4. *Possible Symptoms of Stage IV Lung Cancer* (期肺癌的可能症状)
5. *Treatment Options for Non Small Cell Lung Cancer* (非小细胞肺癌的治疗选择)
6. *Emerging Targeted Therapies for Non Small Cell Lung Cancer* (非小细胞肺癌的新兴靶向治疗)
7. *Amivantamab and Sotorasib as Treatment for Non Small Cell Lung Cancer* (Amivantamab 和 Sotorasib 用于治疗非小细胞肺癌)
8. *Use of Immunotherapy in Stage 1-3 Disease* (免疫疗法在 1-3 期疾病中的应用)
9. *Circulating Tumor DNA* (循环肿瘤DNA)
10. *A Brief Summary of Key Points: Discussion of NSCLC* (要点简述: 非小细胞肺癌的探讨)

Link to videos on GRACE website:

<https://cancergrace.org/video-collection/east-asian-lung-cancer-video-library>





Reach in 2022: 35k+ patients with blood cancer and caregivers reached

Program Overview:

- Patient education video program featuring top oncologists presenting the most current and emerging treatment options
- Short, 3-5 minute easy-to-understand videos as updates to the searchable online GRACE Cancer Video Library
- Videos are transcribed so patients may print them and take them to their health care provider appointment


2022 Program Details/Achievements:


The following topics were subjects of video content for the 2022 program year (videos are still in final production/editing at the time of this report)

1. *New Treatments For Diffuse large B-Cell Lymphoma and Follicular Lymphoma: Bispecific Antibody Therapy*
2. *CLL (Chronic Lymphocytic Leukemia) -- A New Generation of BTK Inhibitors*
3. *Mantle Cell Lymphoma - Exciting Outcomes for CAR-T Cell Therapy Trials*
4. *The Prevalence and Epidemiology of Blood Cancers*
5. *Diagnosis and Management of Blood Cancers*
6. *Management of Treatment of Blood Cancers - Bone Marrow Transplantation and Other Therapies*

Link to videos on GRACE website:

<https://cancergrace.org/video-collection/blood-cancer-video-library>





Reach in 2022: 10k+ patients with bladder cancer and caregivers reached

Program Overview:

- Patient Video program featuring leading oncologists providing short, 3-5 minute topic-specific video updates for our searchable online bladder cancer video library
- Videos are transcribed so patients may print them and take them to their health care provider appointment

2022 Program Details/Achievements:

The following topics were subjects of video content for the 2022 program year (videos are still in final production/editing at the time of this report)

Immunotherapy in Bladder Cancer

1. What is the role of systemic therapy (chemotherapy/ immunotherapy) for neoadjuvant treatment of bladder cancer?
2. What is the role of immunotherapy for unresectable bladder cancer?

3. What is the role of immunotherapy in cisplatin-ineligible bladder cancer (example, renal dysfunction or neuropathy)? Can it be used first-line?
4. What is the role of immunotherapy in frail patients? Can it be used first-line?
5. What is the role of immunotherapy in non-muscle invasive bladder cancer?

Adjuvant treatment for Bladder Cancer


1. What are the indications of administering systemic therapy (chemotherapy/ immunotherapy) post-surgery in bladder cancer?

Biomarkers in Bladder Cancer

1. Do any biomarkers predict response to immunotherapy in bladder cancer?
2. What biomarkers should be performed routinely in bladder cancer?
3. What is the role of genetic sequencing of bladder cancer?

Link to videos on GRACE website:

<https://cancergrace.org/video-collection/bladder-cancer-video-library>





Reach in 2022: 10k+ patients and caregivers reached

Program Overview:

- Patient Video program featuring leading oncologists providing short, 3-5 minute topic-specific video updates for our searchable online melanoma video library
- Videos are transcribed so patients may print them and take them to their health care provider appointment


2022 Program Details/Achievements:

14 Videos produced in 2022:

1. *Melanoma and Current Treatment Options*
2. *Immunotherapy in Treatment of Melanoma*
3. *Side Effects of Immunotherapy in Melanoma*
4. *BRAF Mutated Melanoma*
5. *Major Advances in Uveal Melanoma*
6. *Clinical Trials in Melanoma*
7. *Incidence Trends in Melanoma*
8. *Treatment for Metastatic Melanoma*
9. *Patient Selection for First Line Therapy in Stage 4 Melanoma*
10. *Adjuvant Therapy for Melanoma*
11. *Neoadjuvant Therapy for Melanoma*
12. *Neoadjuvant Therapy in Melanoma: The PRADO Trial*
13. *Neoadjuvant Therapy in Melanoma: Does It Give a Better Immune Response?*
14. *Adjuvant Therapy in Stage 3 and 4 Melanoma*

Link to videos on GRACE website:

<https://cancergrace.org/video-collection/melanoma-video-library>





Reach in 2022: 10k+ patients with cancer and caregivers reached

Program Overview:

- Patient education video program featuring a panel of leading oncologists presenting the most current COVID-19 information it they relates to the cancer journey via short, 3-5 minute easy-to-understand videos
- Videos are transcribed so patients may print them and take them to their health care provider appointment


2022 Program Details/Achievements:

5 Videos produced in 2022 covering the following topics as panel discussions:

1. *Risk Factors for Increased Mortality in Covid+ Patients with Cancer*
2. *Covid-19 Vaccination Recommendations for Patients with Cancer*
3. *Covid-19 Booster Recommendations for Patients with Cancer*
4. *Telehealth and Cancer: Covid-19 Influences*
5. *Additional Covid-19 Vaccine Information for Patients with Cancer*

Link to videos on GRACE website:

<https://cancergrace.org/video-collection/covid-19-and-cancer>





Reach in 2022: 10k+ lung cancer patients

Program Overview:

- Patient education video program featuring top oncologists discussing the latest current and emerging lung cancer updates direct from ASCO in a roundtable discussion format
- Short, 3-5 minute easy-to-understand videos filmed directly following ASCO
- Videos are transcribed so patients may print them and take them to their health care provider appointment


2022 Program Details/Achievements:

10 Videos produced in 2022

1. The Need for Molecular Testing in Lung Cancer
2. Patients with High PD-L1: Immunotherapy Alone or Combine with Chemo?
3. Chemotherapy and Immunotherapy for Patients with KRAS Mutations
4. Adagrasib for Previously Treated KRAS G12C+ NSCLC
5. Keytruda Combined with Anti-VEGF Treatment: Use in Patients with Advanced NSCLC
6. Rybrevant/Lazertinib for EGFRm+ Acquired Resistance
7. EGFRm+ NSCLC: Should We Treat with Durvalumab?
8. Patritumab Deruxtecan: Use in Previously Treated Patients Without Specific Mutations
9. The Skyscraper Trial: Treatments for Extensive Stage Small Cell Lung Cancer
10. Checkmate 816: Combining Chemo and Opdivo

Link to videos on GRACE website:

<https://cancergrace.org/video-collection/asco-lung-roundtable>





Reach in 2022: 5k+ head and neck cancer patients reached

Program Overview:

- *Patient education video program featuring top oncologists discussing the latest current and emerging head and neck cancer updates direct from ASCO in a roundtable discussion format*
- *Short, 3-5 minute easy-to-understand videos filmed directly following ASCO*
- *Videos are transcribed so patients may print them and take them to their health care provider appointment*


2022 Program Details/Achievements:


7 Videos produced in 2022:

1. *Deintensification for Nasopharyngeal Cancer*
2. *Nonsurgical Treatment in Head and Neck Cancer: Weekly Cisplatin*
3. *Immunotherapy Treatments in Patients with Head and Neck Cancer*
4. *Patients with Recurrent or Metastatic Head and Neck Cancer*
5. *Combination Therapy for Head and Neck Cancer*
6. *Circulating Tumor (CT) and HPV DNA*
7. *Emerging Treatments for Oral Mucositis*

Link to videos on GRACE website:

<https://cancergrace.org/video-collection/asco-head-and-neck-cancer-news-and-updates>





Reach in 2022: 15k+ lung cancer patients reached

Program Overview:

- Patient education video program featuring a panel of 3-5 leading oncologists presented with lung cancer specific cases highlighting discussion where the video audience is a “fly on the wall” as panelists brainstorm the best approaches to each case in a casual, non lecture setting
- Videos are transcribed so patients may print them and take them to their health care provider appointment


2022 Program Details/Achievements:

9 Videos produced in 2022:

1. *How Oncologists Stage Disease*
2. *Treating Stage III NSCLC*
3. *Neoadjuvant Chemotherapy +/- Nivolumab for Patients with Early Stage NSCLC*
4. *Treatment Options for EGFR+ NSCLC*
5. *Immunotherapy in Stage III NSCLC*
6. *Treating HER2 Exon-20 Insertion NSCLC with Trastuzumab Deruxtecan (T-DXd)*
7. *Surgical Option for Stage IV NSCLC with Brain Mets*
8. *Treatment for KRAS G12C Mutated NSCLC with High Tumor Mutational Burden*
9. *Sotorasib vs. Adagrasib as Treatment for KRAS G12C Mutated NSCLC*

Link to videos on GRACE website:

<https://cancergrace.org/video-collection/case-based-panel-discussions>





Reach in 2022: 35k+

Program Overview:

- Patient education video program featuring top oncologists presenting the most current and emerging information about vaccinations, testing and therapy related to HPV
- Short, 3-5 minute easy-to-understand videos as updates to the searchable online GRACE Video Library
- Videos are transcribed so patients may print them and take them to their health care provider appointment

2022 Program Details/Achievements:

The following topics were subjects of video content for the 2022 program year (videos are still in final production/editing at the time of this report)

1. Preventative vaccinations
2. Therapeutic vaccinations
3. Therapeutic testing
4. Treatment of R/M
5. Immunoradiotherapy

Link to videos on GRACE website:

<https://cancergrace.org/video-collection/hpv-advances-patient-education-program>





Reach in 2022: 35k+ patients and caregivers

Program Overview:

- Patient education video program featuring top oncologists presenting the most current and emerging information about the importance of testing before and after diagnosis or at recurrence/progression
- Short, 3-5 minute easy-to-understand videos as updates to the searchable online GRACE Cancer Video Library
- Videos are transcribed so patients may print them and take them to their health care provider appointment


2022 Program Details/Achievements:

16 Videos Produced in 2022:

1. Covid and Lung Cancer Screening
2. Who Should Receive Lung Cancer Screening?
3. What is Involved in Lung Cancer Screening?
4. Key Players for Lung Cancer Program Success
5. Goals of Lung Cancer Advocacy
6. Timeliness in Cancer Care
7. Efficiency and Effectiveness of Cancer Care
8. Is My Lung Cancer Mutation Genetic?
9. The Importance of Patient Centered Care
10. The Importance of Prostate Cancer Screening
11. The Prevalence of Breast Cancer and Tools for Early Detection
12. Types of Imaging Tests for Breast Cancer
13. Anomalies on Breast Cancer Imaging: Next Steps
14. Symptoms of Breast Cancer
15. Treatment After Diagnosis of Breast Cancer
16. The Importance of Breast Cancer Screening

Link to videos on GRACE website:

<https://cancergrace.org/video-collection/testing-and-early-diagnosis>





Reach in 2022: 10k+ lung cancer patients reached

Program Overview:

- Live streamed webinar program featuring a panel of top oncologists
- Interactive program includes live streamed real-time audience; includes a Q&A session
- Recorded event is published online as enduring material
- Videos of the recorded event are transcribed so patients may print them and take them to their health care provider appointment

2022 Program Details/Achievements:

Live event was held on December 10, 2022 virtually using Zoom Webinar. Hundreds of 'real-time' attendees had the opportunity to interact with and participate in a live Q&A with the panels.


The event was video recorded and segments published as enduring material, resulting in **30 videos produced in 2022** featuring topics of the panel discussions as follows:

1. Systemic and Local Therapies for Metastatic Disease
2. Studies in Oligometastatic NSCLC: Current Data and Definitions
3. What Factors Determine a Successful Clinical Trial?
4. Current Treatments for Oligometastatic NSCLC
5. Potential Options for Neoadjuvant NSCLC Therapies
6. The CheckMate 816 Trial: The Success of Adjuvant NSCLC Therapies
7. Discussing Biomarkers and PD-L1 Testing with Your Doctor
8. Factors for Positive Outcomes in Consolidative Therapies for NSCLC
9. Trials for Patients with Actionable Mutations, and the Importance of Quality of Life
10. Preoperative Versus Postoperative Treatment
11. Location of Disease: Can Metastatic Locations Predict Success of Treatment?
12. Oncogene-Driven Metastatic NSCLC: Frontline Treatment and Resistance Mechanisms
13. Strategies to Overcome Resistance
14. Overcoming Resistance in EGFR+ NSCLC
15. Overcoming Resistance in ALK+ or KRAS+ NSCLC
16. Overcoming Resistance in ROS1+, RET+, or BRAF+ NSCLC
17. Studies in Anti-PD-L1 Monotherapy for NSCLC
18. Studies in Chemoimmunotherapy
19. Dual Immune Checkpoint Blockade With or Without Chemotherapy
20. Treatments Algorithms for Advanced NSCLC

21. *Molecular Testing: Liquid vs. Tissue, and Insurance Coverage*
22. *How Does PD-L1 Score Affect Treatment Options?*
23. *Preoperative or Postoperative Immunotherapy?*
24. *Oligoprogression on Alectinib: Next Steps*
25. *Treatment of Stage IV NSCLC with High PD-L1 and Atypical Mutation*
26. *Extended Interval Dosing for Pembrolizumab*
27. *Oligoprogression to the Pleural Area: Should Local Therapy Be Used?*
28. *Treating Side Effects from Neoadjuvant Chemoimmunotherapy*
29. *Progression on Pembrolizumab: A Patient Without Actionable Mutations and Low PD-L1*
30. *Advice on Treatment Limitations Associated with Insurance*

Link to videos on GRACE website:

<https://cancergrace.org/video-collection/lung-onctalk>





Reach in 2022 program year: 15k+ patients with blood cancers

Program Overview:

- Live streamed webinar program featuring a panel of top oncologists
- Interactive program includes live streamed real-time audience; includes a Q&A session
- Recorded event is published online as enduring material
- Videos of the recorded event are transcribed so patients may print them and take them to their health care provider appointment

2022 Program Year Details/Achievements:


The event was video recorded and segments published as enduring material, resulting in **36 videos produced in 2022** featuring topics of the panel discussions as follows:

1. What is Multiple Myeloma?
2. Lab Tests in Multiple Myeloma
3. The Spectrum of Disease in Multiple Myeloma
4. Treatment Options for Multiple Myeloma
5. Cellular Therapies in Multiple Myeloma
6. What is Acute Myeloid Leukemia?
7. Genetic Characteristics of Acute Myeloid Leukemia: Implications in Treatment
8. Treatment Options for Newly Diagnosed AML: Venetoclax and Midostaurin
9. Treatment Options for Relapsed or Refractory AML: IDH1, IDH2, and FLT3
10. Future Directions for Treatment of Acute Myeloid Leukemia
11. CAR T-Cell Versus Bispecific Therapies: How Oncologists Determine Treatment
12. Stem Cell Transplants for Patients with Acute Myeloid Leukemia
13. Cellular Therapy Development in Acute Myeloid Leukemia
14. Geriatric Lymphoma: Unique Challenges and Importance of Geriatric Assessment
15. Tailoring Chemotherapy for Geriatric Patients with Advanced Lymphoma
16. Supportive Management: How Can Geriatric Patients with Lymphoma Support Their Care?
17. Advances in Multiple Myeloma: What is Needed to Get to a Cure?
18. Treatment Timing for Multiple Myeloma
19. Approaches for Treatment of Multiple Myeloma
20. Maintenance Treatment in Multiple Myeloma

21. *Risk Adaptive Management for High Risk Multiple Myeloma*
22. *Treating Relapsed Multiple Myeloma*
23. *The Future of Multiple Myeloma Treatment*
24. *Treatment for Geriatric Patients with Aggressive Lymphomas*
25. *Stem Cell Transplants in Multiple Myeloma*
26. *Is There a Preference for Type of CAR T-Cell Treatment?*
27. *Is There a Way to Alleviate the Cost of CAR T-Cell Therapies?*
28. *Is Revumenib Only for Patients With Relapsed/Refractory KMT2A-Rearranged Acute Leukemia?*
29. *What are Next Steps for a Patient with Two Transplants and a Relapse?*
30. *Are There Any Ongoing Trials for Acute Leukemia in Adults?*
31. *How do Treatment Side Effects Differ in the Geriatric Population?*
32. *Multiple Myeloma and Type 2 Diabetes: First Steps*
33. *What Are the Pros and Cons of CAR T-Cell Therapy vs. Bispecific Antibodies?*
34. *Should Cellular Therapies Be Moved to First Line Treatment?*
35. *How do I Find Clinical Trials?*
36. *Does Smoking or Family History Increase the Risk of Acute Myeloid Leukemia?*

Link to videos on GRACE website:

<https://cancergrace.org/video-collection/blood-cancer-onctalk>





Reach in 2022 from July 2022 program: 5,000+ views/attendees estimated through 12/31/22 with content available as enduring material for 1 year. Estimating 10,000+ views of content in the first 12 months.

- 1/2 day live virtual event featuring top oncologists discussing current and emerging information with live audience
- Break out sessions address rare mutations and targeted information
- Interactive program includes live audience and Q&A sessions
- Recorded event is published online as enduring material
- Videos of the recorded event are transcribed so patients may print them and take them to their health care provider appointment

Live virtual event was held on July 16, 2022 virtually. Hundreds of real-time attendees from around the world viewed the program live and had the opportunity to interact with and participate in a live Q&A with the panels. **84 videos were produced for the 2022 program:**

1. Changes in the Field of Metastatic NSCLC
2. Prevalence of Targeted Driver Mutations in NSCLC
3. Advantages of Next Generation Sequencing (NGS) in NSCLC
4. Treatment of EGFR Mutated NSCLC
5. Acquired Resistance to Osimertinib in EGFR+ NSCLC
6. Amivantamab and Lazertinib in EGFR MET+ Disease
7. The ADAURA Trial: Osimertinib for Early Stage EGFR+ NSCLC
8. Exon 20 and HER2: The Destiny Trial
9. KRAS Mutations in Advanced NSCLC
10. Advanced ALK+, RET+ and MET+ NSCLC
11. Liquid Biopsies in NSCLC


12. Biomarker Testing for NSCLC: The Importance and the Disparities
13. What is Oligoprogression?
14. Identifying Oligoprogression in a Patient
15. Treatment of Oligoprogression
16. Oligoprogression in EGFR Mutant NSCLC
17. Dermatologic Side Effects of EGFR-TKIs
18. Managing Side Effects of EGFR-TKIs: Stomatitis and Diarrhea
19. Side Effects of EGFR-TKIs: Pneumonitis and Cardiotoxicity
20. Side Effects of ALK-TKIs
21. Side Effects of ROS1-TKIs
22. Which Patients Should Receive Next Generation Sequencing (NGS)?
23. Should we use DNA or RNA for NGS?
24. Do Side Effects Signify Better Response to Treatment?
25. Oligoprogression with Non-EGFR Mutations
26. EGFR Mutated NSCLC with Brain Metastasis
27. EGFR Mutated NSCLC Disease Progression on Osimertinib
28. Developing Nodularities on Alectinib: Is It Pneumonitis?
29. New Lesion After Reduced Alectinib: Should Chemo and Pemetrexed Be Added?
30. EGFR+ and Pneumonitis: Treatments Other Than Erlotinib
31. Stage 4 ALK+ Disease: Development of L1196M on Lorlatinib
32. Do Side Effects of TKIs Decrease Over Time?
33. What is EGFR in Lung Cancer?
34. EGFR TKIs and Their Side Effects
35. What if Osimertinib Stops Working?
36. Amivantamab and Lazertinib in Patients with EGFR+ NSCLC
37. Efficacy and Safety of Patritumab Deruxtecán for Patients with EGFR+ NSCLC
38. ALK+ NSCLC: What Does it Mean?
39. ALK+ NSCLC Treatment Options
40. ALK TKI Side Effects and Acquired Resistance
41. Emerging Therapies in ALK+ NSCLC

42. *EGFR TKIs: Efficacy, Combinations, and Use After Chemotherapy*
43. *Side Effects: Treating Mouth Sores and Finding Clinical Trials*
44. *EGFR Mutations: Uncommon Mutation Treatment, and Insurance Complications*
45. *Disease Progression on Lorlatinib or Osimertinib*
46. *Traveling for a Clinical Trial*
47. *Evolution of Therapy in Lung Cancer*
48. *ROS1+ NSCLC: Diagnosing and Treatment*
49. *ROS1 Treatment Options: Crizotinib and Entrectinib*
50. *ROS1 Treatment Options: Lorlatinib and Repotrectinib*
51. *ROS1+ NSCLC: Chemotherapy and Immunotherapy*
52. *Evolving Treatment for NSCLC: Targeted Therapies*
53. *Treatment of HER2+ NSCLC*
54. *Trials in HER2+ NSCLC*
55. *ROS1+ NSCLC: Is It Possible to Develop a Second Mutation?*
56. *HER2+ NSCLC: When to Introduce Targeted Therapies*
57. *ROS1+ NSCLC: Adjuvant Treatment, and the Importance of Testing*
58. *Does Hormonal Therapy Reduce Response to Treatment?*
59. *BRAF Mutations in NSCLC*
60. *BRAF/MEK Combination in BRAF V600E+ Disease*
61. *BRAF+ Disease: BRAF/MEK Combo in Other Mutations*
62. *What are NTRK Mutations?*
63. *Testing for NTRK Mutations in NSCLC*
64. *Treatment Options for NTRK+ NSCLC: Larotrectinib and Entrectinib*
65. *First Line Therapy for BRAF+ and NTRK+ NSCLC*
66. *BRAF and NTRK Inhibitors: Their Role in Early NSCLC*
67. *RNA or DNA: Which NGS Test To Use*
68. *KRAS+ NSCLC: Prevalence and the Evolution of Treatment*
69. *Treatment Timelines for KRAS+ NSCLC*
70. *Types of Biopsies for KRAS+ NSCLC*
71. *Treatment Strategies for KRAS+ NSCLC*

72. *RET+ NSCLC: A Case Study*
73. *How to Identify RET+ NSCLC*
74. *RET+ NSCLC Treatment Options*
75. *An Advocate's Story: Finding Your Community*
76. *KRAS Treatments and Clinical Trials*
77. *Treatment Options for RET+ NSCLC: Selpercatinib vs. Pralsetinib*
78. *Advice for Newly Diagnosed Patients*
79. *Handling the Stress of Scans*
80. *Progression on Sotorasib with KRAS+ NSCLC*
81. *When Should Progression Lead to Treatment Changes?*
82. *Talking to Loved Ones About Your Diagnosis*
83. *Finding Resources for Patient and Caregivers*
84. *Nutrition During Cancer Treatment*

Link to videos on GRACE website:

<https://cancergrace.org/video-collection/targeted-therapies-patient-forum-english>





Reach in 2022 from July 2022 program: 5,000+ views/attendees estimated through 12/31/22 with content available as enduring material for 1 year. Estimating 10,000+ views of content in the first 12 months.

- 2.5 hour live event featuring top oncologists from the US, Columbia and Costa Rica discussing current and emerging information with live audience
- Panel discussions address rare mutations and targeted information
- Interactive program includes live audience and Q&A sessions
- Recorded event is published online as enduring material
- Videos of the recorded event are transcribed so patients may print them and take them to their health care provider appointment

Live event was held on July 30, 2022 virtually using Zoom Webinar. Hundreds of 'real-time' attendees from around the world viewed the program and had the opportunity to interact with and participate in a live Q&A with the panels.


22 videos were produced for the 2022 Spanish-Language Targeted Therapies Forum:

1. *Un Estudio de Caso y la Importancia de las Pruebas NGS en la Enfermedad ALK y ROS1*
2. *Diferencias en las Pruebas de Cáncer de Pulmón en América Latina y los Estados Unidos*
3. *Biopsias Líquidas: Su Papel en la Atención de Pacientes con Cáncer de Pulmón*
4. *Un Estudio de Caso de Cáncer de Pulmón ALK+*

5. *Un Paciente ALK+ con Progresión de la Enfermedad Durante el Tratamiento: Un Estudio de Caso*
6. *Estudio de Caso: Paciente ALK+ con Múltiples Mutaciones Resistentes a ALK*
7. *Un Estudio de Caso: Un Paciente con Enfermedad Metastásica ROS1+*
8. *Biopsia de Tejido Versus Biopsia Líquida*
9. *Tendencias y Datos de NGS*
10. *El Papel de la Biopsia Líquida en la Enfermedad Progresiva*
11. *El Futuro de la Biopsia Líquida*
12. *Osimertinib para Enfermedad EGFR+*
13. *Progresión de la Enfermedad en Pacientes con NSCLC EGFR+*
14. *ALK+ NSCLC: Tratamiento y Progresión*
15. *La Importancia de la Terapia Dirigida en NSCLC*
16. *El Ensayo ADAURA: Tratamiento Adyuvante con Osimertinib*
17. *La Prevalencia de las Pruebas de EGFR en NSCLC en Etapa Temprana*
18. *Ensayos de Terapia Dirigida: Osimertinib, Atezolizumab, Quimioterapia y Más*
19. *Preguntas y Respuestas Parte 1: Osimertinib*
20. *Preguntas y Respuestas Parte 2: Enfermedad Metastásica, Medicamentos y Biopsias*
21. *Preguntas y Respuestas Parte 3: Efectos Secundarios y Mutaciones*
22. *Preguntas y Respuestas Parte 4: Enfermedad Metastásica, Biopsias, TKI, y Efectos Secundarios*

Link to videos on GRACE website:

<https://cancergrace.org/video-collection/targeted-therapies-patient-forum-spanish>



Reach in 2022: 5k+ Patients with cancer and caregivers

Program Overview:

- Patient advocates create new content for the GRACE video library based on their clinical trials journey
- Content is presented through storytelling as an educational tool for patients considering a clinical trial
- Short, 3-5 minute easy-to-understand videos as updates to the searchable online GRACE Cancer Video Library
- Videos are transcribed so patients may print them and take them to their health care provider appointment

2022 Program Details/Achievements:

7 Video produced in 2022:

1. Ovarian cancer clinical trials experiences:
 - a. Family History and a Diagnosis - 3 Years and 3 Trials
 - b. Covid and Clinical Trials - Changing the Rules - 3 Years and 3 Trials
2. Breast cancer clinical trials experiences:
 - a. Path to Breast Cancer Diagnosis
 - b. Clinical Trials Doubts and Questions, Financial Concerns
 - c. Racial Disparities in Clinical Trials
 - d. Mental Health in Clinical Trials
 - e. Advice from a Clinical Trial Participant

Link to videos on GRACE website:

<https://cancergrace.org/video-collection/clinical-trials-through-storytelling>





Reach in 2022: 15k+ patients with cancer & caregivers reached

Program Overview:

- Fellows and finishing Fellows are recruited to expand and create new content for the GRACE patient education library based on their specialty.
- A portion of this program focuses on communication strategies as they enter their practice.
- Content is created in audio (podcast), written and video formats. Videos are transcribed so patients may print them and take them to their health care provider appointment

2022 Program Details/Achievements:

24 pieces of content to be produced in the 2022 program:


The 2022 program year for the Patient Education Ambassadors program runs from July 1, 2022 - June 30, 2023. Highlights of this program's past patient education content, and planned content, include:

- 2019-2020 program year: 2 Fellows selected and content produced:
 - Dr. Arjun Gupta: Supportive Care
 - Dr. Narjust Duma: Latino and minority concerns, myths and advocacy
- 2020-2021 program year: 4 Fellows selected and content produced:

- Dr. Ana Manana Velazquez: Latino and minority concerns and advocacy regarding COVID-19 with Dr. Idalid Franco as well as content about radiation oncology
- Dr. Abdul Rafeh Naqash: Clinical trials education and minority reac)
- Dr. Idalid Franco: Latino and minority concerns and advocacy regarding COVID-19 with Dr. Ana Manana Velazquez as well as content about radiation oncology)
- Dr. Medhavi Gupta: Healthcare disparities; breast cancer)
- 2021-2022 program year: 4 Fellows selected and content produced
 - Dr. Aakash Desai: health disparities and infographics for patients in India and Nepal
 - Dr. Daniel Kwon: Prostate cancer and decision aids
 - Dr. Edina Wang: Chinese health literacy and radiation oncology
 - Dr. Eric Singhi: Misinformation mitigation and reaching medically underserved
- 2022-2023 program year: 4 Fellows selected. Content to be produced in early 2023
 - Dr. Ashish Gupta: First steps after diagnosis, GI treatments
 - Dr. Mazie Tsang: Decision making tools, geriatric lymphoma patient education
 - Dr. Sridevi Rajeeve: CAR T-Cell patient education, lymphoma and myeloma patient education
 - Dr. Fernando Diaz: Patient education for latino patient community, first steps after diagnosis

Link to videos on GRACE website:

<https://cancergrace.org/video-collection/patient-education-ambassador-program>






Reach/Metrics: This program publishes one podcast each week. Listener metrics of 500 for each podcast released and published online for future listening was anticipated within 1 year of each podcast release, totaling over 25,000 'listens' to the 2022 podcast program.

- Podcast program covering the most current and emerging treatment options which supports the content in the other GRACE programs such as lung cancer, blood cancers, and bladder cancer via an alternate delivery method and additional content
- Features leading oncologists in each 5-20 minute episode
- One episode will be published per week for 52 weeks designed to help patients by providing an innovative access point
- Program supports other GRACE programs by offering access to patient education in an alternative method, allowing patients to watch videos, read articles, and now listen to this educational information while driving, cooking, etc. This will greatly broaden our patient reach.


2022 Program Details/Achievements:

- Weekly podcast produced and published all 52 weeks in 2022
- Please see full list of podcasts at: <https://cancergrace.org/grace-podcasts>



Online Forum

Reach/Metrics: The GRACE website receives over 1,000,000 visitors each year, and the Online Forum is one of the main features of our website. Our Online Forum receives thousands of new topic threads each year, creating a hub of information on our website. Please visit our Online Forum at: <https://cancergrace.org/forums>



GRACENotes eNewsletter

Subscribe to GRACENotes - the Free Member Newsletter for cancerGRACE.org



Reach/Metrics: The semi-monthly GRACE newsletter, GRACENotes reaches over 1,000,000 patients each year through direct distribution

and online publishing. The newsletter features new program information as well as links to threads on our Online Forum, creating a valuable, concise resource for patients to drill down to educational content and stay abreast of new content we are publishing throughout the year.

Get help, ask a question, share experiences and information

Ask a Question

GRACE's 2022 Global Reach: Patients/Caregivers in 193 Countries Reached (Outside of the United States)

Afghanistan	63
Albania	24
Algeria	26
American Samoa	14
Andorra	247
Angola	5
Antarctica	5
Antigua & Barbuda	5
Argentina	52
Armenia	8
Aruba	1
Australia	3,481
Austria	99
Azerbaijan	9
Bahamas	9
Bahrain	12
Bangladesh	144

Barbados	6
Belarus	4
Belgium	163
Belize	7
Benin	97
Bermuda	10
Bhutan	1
Bolivia	9
Bosnia & Herzegovina	66
Botswana	3
Brazil	236
British Virgin Islands	5
Brunei	15
Bulgaria	65
Burkina Faso	3
Cambodia	12
Cameroon	9
Canada	6,909
Cape Verde	1
Caribbean Netherlands	1
Cayman Islands	4
Chad	1
Chile	43
China	108,156

Colombia	71
Congo - Kinshasa	6
Costa Rica	27
Côte d'Ivoire	7
Croatia	371
Cuba	4
Curacao	1
Cyprus	30
Czechia	334
Denmark	77
Djibouti	1
Dominica	3
Dominican Republic	15
Ecuador	23
Egypt	173
El Salvador	71
Equatorial Guinea	1
Estonia	28
Ethiopia	43
Faroe Islands	1
Fiji	8
Finland	116
France	1,140
Gambia	1

Georgia	14
Germany	3,067
Ghana	22
Gibraltar	2
Greece	156
Grenada	1
Guam	3
Guatemala	12
Guernsey	4
Guinea	1
Guyana	4
Haiti	3
Honduras	4
Hong Kong	417
Hungary	83
Iceland	14
India	19,060
Indonesia	672
Iran	89
Iraq	51
Ireland	640
Israel	143
Italy	368
Jamaica	15

Japan	240
Jersey	7
Jordan	49
Kazakhstan	15
Kenya	66
Kosovo	11
Kuwait	24
Kyrgyzstan	3
Laos	10
Latvia	11
Lebanon	46
Lesotho	1
Libya	9
Liechtenstein	3
Lithuania	39
Luxembourg	14
Macao	3
Madagascar	5
Malawi	1
Malaysia	683
Maldives	5
Mali	2
Malta	20
Martinique	3

Mauritius	14
Mexico	165
Moldova	7
Monaco	3
Mongolia	2
Montenegro	13
Morocco	35
Mozambique	3
Myanmar (Burma)	19
Namibia	8
Nepal	45
Netherlands	1,336
New Caledonia	1
New Zealand	330
Nicaragua	3
Niger	4
Nigeria	173
North Macedonia	89
Norway	103
Oman	13
Pakistan	918
Palestine	11
Panama	18
Papua New Guinea	2

Paraguay	3
Peru	50
Philippines	2,005
Poland	172
Portugal	88
Puerto Rico	51
Qatar	24
Réunion	1
Romania	236
Russia	377
Rwanda	3
Samoa	1
San Marino	2
Saudi Arabia	183
Senegal	3
Serbia	106
Seychelles	275
Sierra Leone	6
Singapore	408
Slovakia	47
Slovenia	61
Somalia	2
South Africa	250
South Korea	271

South Sudan	1
Spain	418
Sri Lanka	30
St. Barthelemy	1
St. Martin	1
St. Pierre & Miquelon	15
Sudan	13
Suriname	2
Sweden	255
Switzerland	146
Syria	9
Taiwan	217
Tajikistan	1
Tanzania	16
Thailand	186
Togo	1
Trinidad & Tobago	14
Tunisia	15
Turkey	208
U.S. Virgin Islands	2
Uganda	34
Ukraine	234
United Arab Emirates	155
United Kingdom	15,019

Uruguay	12
Uzbekistan	16
Venezuela	21
Vietnam	129
Yemen	6
Zambia	8
Zimbabwe	5

Total reach outside the United States	173,827
--	----------------